OKYO Pharma Advances Lead Candidate Urcosimod with Positive Phase 2 Data and Pivotal Trial Plans

summarizeSummary

This filing provides a significant positive update on OKYO Pharma's lead candidate, urcosimod, for neuropathic corneal pain (NCP). The announcement of positive Phase 2 clinical data, coupled with a Scientific Advisory Board meeting and presentation at a major ophthalmology conference (ASCRS), signals strong progress in the drug's development. The plan to initiate a pivotal Phase 2b/3 study in the first half of 2026, along with the existing Fast Track designation, indicates an accelerated path to market for a therapy addressing a significant unmet medical need. This positive development is particularly important for OKYO Pharma, which previously disclosed a 'going concern' warning and established a dilutive ATM program. Successful clinical advancement of urcosimod could be crucial for the company's long-term viability and ability to secure future funding.

check_boxKey Events

• Positive Phase 2 Data for Urcosimod

  The company announced positive efficacy and safety results from a proof-of-concept pilot Phase 2 study of urcosimod in neuropathic corneal pain (NCP) patients, showing clear statistical significance in multiple endpoints.

• Strategic Scientific Advisory Board Meeting

  OKYO Pharma will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts to review clinical data for urcosimod and provide strategic guidance on the upcoming clinical program.

• Presentation at ASCRS Annual Meeting

  Dr. Pedram Hamrah, a principal investigator, will present the Phase 2 efficacy and safety results for urcosimod at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

• Plans for Pivotal Phase 2b/3 Study

  The company plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of 2026.

auto_awesomeAnalysis

This filing provides a significant positive update on OKYO Pharma's lead candidate, urcosimod, for neuropathic corneal pain (NCP). The announcement of positive Phase 2 clinical data, coupled with a Scientific Advisory Board meeting and presentation at a major ophthalmology conference (ASCRS), signals strong progress in the drug's development. The plan to initiate a pivotal Phase 2b/3 study in the first half of 2026, along with the existing Fast Track designation, indicates an accelerated path to market for a therapy addressing a significant unmet medical need. This positive development is particularly important for OKYO Pharma, which previously disclosed a 'going concern' warning and established a dilutive ATM program. Successful clinical advancement of urcosimod could be crucial for the company's long-term viability and ability to secure future funding.